Transforming oncology clinical trial matching through neuro-symbolic, multi-agent AI and an oncology-specific knowledge graph: a prospective evaluation in 3804 patients.

A Loaiza-Bonilla^1,2, C Yost³, S Kurnaz², E Tuysuz², N G Thaker⁴, D Giritlioglu², J P Noel Meza²

¹St. Luke's University Health Network, Easton, USA.

²Massive Bio, Inc., Boca Raton, USA.

³Creighton University School of Medicine, Phoenix, USA.

⁴Capital Health, Pennington, USA.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Clinical trial enrollment in oncology remains critically low, with fewer than 5% of eligible adults participating, in large part due to the complexity and labor intensity of eligibility screening. We prospectively evaluated a neuro-symbolic, multi-agent artificial intelligence (AI) platform integrating domain-specific large language model (LLM) agents, an oncology-specific knowledge gr…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.